NASDAQ
71.93USD
-1.94 (-2.63%)
We have scored 9 news catalysts on Oruka Therapeutics, Inc. (ORKA) over the past 12 months. The biggest single-day move next to one of them came Mar 14, 2026, when ORKA closed +25.0%: “Oruka Therapeutics (NASDAQ:ORKA) Reaches New 1-Year High After Better-Than-Expected Earnings”. Coverage across the window leans positive (average ticker sentiment +0.74). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
4.8B
P/E
—
EPS
—
Beta
-0.39
52W range
25.11-115.52
Day range
70.55–73.80
Open
73.28
Prev close
73.87
Volume
1.4M
Avg volume
1.1M
Dividend
0.00
IPO
1997-08-08
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Oruka Therapeutics, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ORKA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
